nyuuzyou/wikis huggingface dataset:
Adagrasib (Krazati)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling.
*IUPHAR/BPS
==Diseases for which it is used==
*Colorectal cancer, KRAS-mutated
*Non-small cell lung cancer, KRAS-mutated
==History of changes in FDA indication==
*2022-12-12: Granted accelerated approval for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. (Based on KRYSTAL-1NSCLC)
*2024-06-21: Granted accelerated approval in combination with cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Based on KRYSTAL-1CRC)
==History of changes in EMA indication==
*2023-11-09: CHMP recommendation for conditional marketing authorisation - KRAZATI as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.
==Also known as==
*Code name: MRTX-849
*Brand name: Krazati
Category:Drugs
Category:Oral medications
Category:KRAS inhibitors
Category:Colorectal cancer medications
Category:Non-small cell lung cancer medications
Category:FDA approved in 2022
Adavosertib (MK-1775)

==Mechanism of action==
From the NCI Drug Dictionary: A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Ovarian cancer===
#PHL-093: Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, Fleming GF, Welch S, Dhani NC, Stockley T, Rath P, Karakasis K, Jones GN, Jenkins S, Rodriguez-Canales J, Tracy M, Tan Q, Bowering V, Udagani S, Wang L, Kunos CA, Chen E, Pugh TJ, Oza AM. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 Jan 23;397(10271):281-292. link to original article link to PMC article EuroPMC NCT02101775
==Also known as==
*Code names: AZD-1775, MK-1775
Category:Drugs
Category:Oral medications
Category:WEE1 inhibitors
Category:Ovarian cancer medications (investigational)
Category:Investigational drugs
Adebrelimab (SHR-1316)

==Mechanism of action==
*From the NCI Drug Dictionary: An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells.
==Also known as==
*Code names: HTI-1088, SHR-1316
Category:Drugs
Category:Intravenous medications
Category:T-cell activators
Category:Anti-PD-L1 antibodies
Category:Small cell lung cancer medications (investigational)
Category:Investigational drugs
Category:Stub
Adrenocortical carcinoma - null regimens

The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main adrenocortical carcinoma page for regimens that include active anticancer treatment.
=Adjuvant therapy=
==Observation==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy
Terzolo et al. 2023 (ADIUVO)	2008-10-23 to 2018-12-27	Phase 3 (C)	Mitotane 	Did not meet primary endpoint of RFS
====Preceding treatment====
*Adrenalectomy
No further treatment.
===References===
#ADIUVO: Terzolo M, Fassnacht M, Perotti P, Libé R, Kastelan D, Lacroix A, Arlt W, Haak HR, Loli P, Decoudier B, Lasolle H, Quinkler M, Haissaguerre M, Chabre O, Caron P, Stigliano A, Giordano R, Zatelli MC, Bancos I, Fragoso MCBV, Canu L, Luconi M, Puglisi S, Basile V, Reimondo G, Kroiss M, Megerle F, Hahner S, Kimpel O, Dusek T, Nölting S, Bourdeau I, Chortis V, Ettaieb MH, Cosentini D, Grisanti S, Baudin E, Berchialla P, Bovis F, Sormani MP, Bruzzi P, Beuschlein F, Bertherat J, Berruti A. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol. 2023 Oct;11(10):720-730. Epub 2023 Aug 21. link to original article link to PMC article EuroPMC NCT00777244
=Recurrent, locally advanced, or metastatic disease=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Fassnacht et al. 2015 (GALACCTIC)	2009-2011 	Phase 3 (C)	Linsitinib	Did not meet primary endpoint of OSMedian OS: 356 vs 323 days
No active antineoplastic treatment.
===References===
# GALACCTIC: Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. link to original article EuroPMC NCT00924989
Category:Adrenocortical carcinoma regimens
Category:Disease-specific pages
Category:Endocrine cancers
Category:Null regimens
Adult T-cell leukemia-lymphoma - historical

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main ATCLL page for current regimens.
Last updated on 2024-07-23:2 regimens on this page
2 variants on this page
 
=Untreated=
==Interferon alfa-2b & Zidovudine==
===Regimen===
Study 	Dates of enrollment	Evidence
Gill et al. 1995	Not reported 	Non-randomized, fewer than 20 pts
====Immunotherapy====
*Interferon alfa-2b (Intron-A) as follows:
**Cycle 1: 5,000,000 units SC once per day on days 1 to 7
**Cycles 2 to 52: 10,000,000 units SC once per day on days 1 to 7
*Zidovudine (Retrovir) 200 mg PO five times per day
7-day cycle for up to 52 cycles or at least 4 cycles past documented CR
===References===
# Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995 Jun 29;332(26):1744-8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==LSG15==
===Regimen===
Study 	Dates of enrollment	Evidence
Yamada et al. 2001 (JCOG 9303)	1994-1996 	Phase 2
Note: Ranimustine is not available in the United States and is approved only in Japan. This regimen was notable for excess CNS relapses and was subsequently replaced by mLSG15.
====Chemotherapy====
*Vincristine (Oncovin) 1 mg/m2 (maximum dose of 2 mg) IV once on day 1
*Cyclophosphamide (Cytoxan) 350 mg/m2 IV once on day 1
*Doxorubicin (Adriamycin) 40 mg/m2 IV once on day 1, then 30 mg/m2 IV once on day 8
*Ranimustine (Cymerin) 60 mg/m2 IV once on day 8
*Vindesine (Eldisine) 2.4 mg/m2 IV once on day 15
*Etoposide (Vepesid) 100 mg/m2 IV once per day on days 15 to 17
*Carboplatin (Paraplatin) 250 mg/m2 IV once on day 15
====Glucocorticoid therapy====
*Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1, 8, 15 to 17
28-day cycle for 7 cycles
===References===
# JCOG 9303: Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001 May;113(2):375-82. link to original article EuroPMC
Category:Adult T-cell leukemia-lymphoma regimens
Category:Disease-specific pages
Category:Acute leukemias
Category:T-cell lymphomas
Category:T-cell leukemias
Category:Historical regimens
Afamitresgene autoleucel (Tecelra)

==Mechanism of action==
From the NCI Drug Dictionary: A preparation of autologous human T-lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells.
==Diseases for which it is used==
*Liposarcoma
*Synovial sarcoma
==History of changes in FDA indication==
*2024-08-02: Granted accelerated approval for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. (Based on SPEARHEAD-1)
==Also known as==
*Code name: ADP-A2M4
*Generic name: afami-cel
*Brand name: Tecelra
Category:Drugs
Category:Intravenous medications
Category:Mutation-specific medications
Category:Protein expression-specific medications
Category:Anti-MAGE-A4 SPEAR T-cells
Category:Liposarcoma medications
Category:Synovial sarcoma medications
Category:FDA approved in 2024
Afuresertib (GSK-2110183)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Multiple myeloma===
# PKB112835: Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. link to original article link to PMC article EuroPMC NCT00881946
==Also known as==
*Code names: GSK-2110183, LAE-002
Category:Drugs
Category:Oral medications
Category:AKT1 inhibitors
Category:Multiple myeloma medications (investigational)
Category:Investigational drugs
Agatolimod (PF-3512676)

==Mechanism of action==
From the NCI Drug Dictionary: The tricosasodium salt of a synthetic 24-mer oligonucleotide containing 3 CpG motifs with potential antineoplastic and immunostimulatory activity. Agatolimod selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens.
==Also known as==
*Code name: PF-3512676
Category:Drugs
Category:Intravenous medications
Category:TLR9 agonists
Category:Investigational drugs
Aggressive Non-Hodgkin lymphoma

=Aggressive B-cell non-Hodgkin lymphoma regimens have been moved to their histology-specific subtype pages. Please use the links below and/or update your bookmarks.=
==Diffuse large B-cell lymphoma (DLBCL)==
==Burkitt lymphoma (BL) or Burkitt-like lymphoma==
==Mediastinal gray-zone lymphoma (MGZL)==
==Primary mediastinal B-cell lymphoma (PMBL)==
==Transformed lymphoma (TL)==
Category:Obsolete pages
Aldesleukin (Proleukin)

==General information==
Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.Aldesleukin (Proleukin) package insert Aldesleukin (Proleukin) package insert (locally hosted backup)Proleukin manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is established (work in progress)==
*Renal cell carcinoma
==Diseases for which it is used==
*Melanoma
*Neuroblastoma
==Patient drug information==
*Aldesleukin (Proleukin) patient drug information (Chemocare)Aldesleukin (Proleukin) patient drug information (Chemocare)
*Aldesleukin (Proleukin) patient drug information (UpToDate)Aldesleukin (Proleukin) patient drug information (UpToDate)
==History of changes in FDA indication==
*1992-05-05: Initial approval for treatment of adults (>18 years old) with metastatic renal cell carcinoma. (Based on Fyfe et al. 1995)
*Uncertain date: Approved for the treatment of adults with metastatic melanoma. (Based on Atkins et al. 1999)
==History of changes in EMA indication==
*1989-07-03: EURD
==History of changes in PMDA indication==
*2021-06-23: New indication and a new dosage for the enhancement of an antitumor effect of dinutuximab (genetical recombination) for neuroblastoma.
==Also known as==
*Code name: ILT-101
*Generic names: Interleukin-2, IL-2
*Brand names: Macrolin, Proleukin, Teceleukin
==References==
Category:Drugs
Category:Intravenous medications
Category:Interleukins
Category:T-cell activators
Category:Melanoma medications
Category:Neuroblastoma medications 
Category:Renal_cell_carcinoma medications
Category:FDA approved in 1992
Category:EMA approved in 1989
Alendronate (Fosamax)

==General information==
Class/mechanism: Bisphosphonate, inhibits osteoclast activity, dissolution of hydroxyapatite crystals, and bone resorption/turnover.Alendronate (Fosamax) package insert Alendronate (Fosamax) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Patient drug information==
*Patient counseling information can be found on page 22-23 of the Alendronate (Fosamax) package insert
*Alendronate (Fosamax) patient drug information (UpToDate)Alendronate (Fosamax) patient drug information (UpToDate)
==Also known as==
*Generic names: acide alendronique, acido alendronico, alendronic acid
*Brand names:
Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms
Adronat 	Aidbone 	Aldren 	Aldronac 	Alemax 	Alenat 	Alenato 	Alenbon
Alend 	Alendene 	Alendex 	Alendil 	Alendomax 	Alendon 	Alendor 	Alendra 7
Alendral 	Alendrate 	Alendrin 	Alendro 	Alendromax 	Alendron 	Alendronat 	Alendronato
Alendronhexal	Alendroninezr	Alendroninezuur	Alendronsaeure	Alendronstad	Alendros 	Alenmax 	Alenost
Alent 	Alentop 	Aliot 	Allenmax 	Alont 	Alovell 	Apodrolen 	Arendal
Armol 	Arond 	Berlex 	Bifemelan 	Bifosa 	Bifosmac 	Binosto 	Bisbon
Blindafe 	Bolend 	Bonaid 	Bonalon 	Bonamax 	Bonapex 	Bonemax 	Bongard
Bonmax 	Bonomax 	Bostrong 	Brek 	Calidron 	Cleveron 	Defixal 	Denfos
Drate 	Dronadil 	Dronal 	Dronalent 	Dronat 	Drovitan 	Durost 	Elandur
Endronal 	Endronax 	Endrostan 	Endrox 	Eucalen 	Findeclin	Firmofos 	Fixopan
Folend 	Forenmax 	Fosaalen 	Fosalan 	Fosalen 	Fosalong 	Fosamac 	Fosamax
Fosanet 	Fosaqueen 	Fosavance 	Fosfalen 	Fosfoplus 	Fosmin 	Fostepor 	Fosval
Genalen 	Genalmen 	Gerical 	Gynodron 	Holadren 	Lafedam 	Landrolen 	Lendronal
Leodrin 	Lindron 	Lokar 	Marvil 	Maxibone 	Minusorb 	Nichospor 	Onclast
Orthonate 	Osalen 	Osaston 	Osdronat 	Oseolen 	Oseomax 	Oseotal 	Oseotenk
Osficar 	Oslene 	Ossifix 	Ossomax 	Ostat 	Ostel 	Ostemax Comfort	Ostenan
Osteobon 	Osteodur 	Osteofar 	Osteofel 	Osteofene 	Osteofos 	Osteofose 	Osteomax
Osteomed 	Osteomel 	Osteomepha 	Osteomix 	Osteonato 	Osteoral 	Osteotec 	Osteotrat
Ostex 	Ostolek 	Ostonat 	Oxtalen 	Phostarac 	Poris 	Porosal 	Porosin
Ralenost 	Recalfe 	Regenesis 	Rekostin 	Restofos 	Reventa 	Romax 	Silidral
Sinfract 	Synostep 	Teiroc 	Terost 	Tevalen 	Tevanate 	Tibolene 	Tibone
Tilios 	Voroste 	Zophost 	 	 	 	 	
==References==
Category:Drugs
Category:Oral medications
Category:Bisphosphonates
Category:FDA approved in 1995
Alisertib (MLN-8237)

==Mechanism of action==
From the NCI Drug Dictionary: A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Mantle cell lymphoma===
# C14004: Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. link to original article link to PMC article EuroPMC NCT00807495
===Peripheral T-cell lymphoma===
# SWOG S1108: Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol. 2015 Jul 20;33(21):2399-404. Epub 2015 Jun 15. link to original article link to PMC article EuroPMC NCT01466881
# LUMIERE: Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019 Mar 10;37(8):613-623. Epub 2019 Feb 1. link to original article link to PMC article EuroPMC NCT01482962
==Also known as==
*Code name: MLN-8237
Category:Drugs
Category:Oral medications
Category:Aurora kinase inhibitors
Category:Mantle cell lymphoma medications (investigational)
Category:Peripheral T-cell lymphoma medications (investigational)
Category:Investigational drugs
Alitretinoin (Panretin)

==Mechanism of action==
From the NCI Drug Dictionary: An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.
==Diseases for which it is used==
*Kaposi sarcoma
== Patient Drug Information==
*Alitretinoin (Panretin) Package InsertAlitretinoin (Panretin) Package Insert
==History of changes in FDA indication==
*1999-02-02: Initial approval for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. (Based on Walmsley et al. 1999 & Bodsworth et al. 2001)
==Also known as==
*Code names: ALRT-1057, LGD-1057
*Brand names: Panretin, Panretyn, Panrexin
==References==
Category:Drugs
Category:Topical medications
Category:Retinoids
Category:Kaposi sarcoma medications
Category:FDA approved in 1999